Akero Therapeutics (NASDAQ:AKRO) COO Sells $597,000.00 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young sold 12,500 shares of Akero Therapeutics stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $47.76, for a total value of $597,000.00. Following the completion of the transaction, the chief operating officer directly owned 196,898 shares of the company’s stock, valued at $9,403,848.48. This represents a 5.97% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Jonathan Young also recently made the following trade(s):

• On Thursday, September 11th, Jonathan Young sold 586 shares of Akero Therapeutics stock. The shares were sold at an average price of $43.02, for a total value of $25,209.72.
• On Tuesday, September 2nd, Jonathan Young sold 12,500 shares of Akero Therapeutics stock. The shares were sold at an average price of $46.08, for a total value of $576,000.00.
• On Tuesday, August 12th, Jonathan Young sold 12,500 shares of Akero Therapeutics stock. The shares were sold at an average price of $47.79, for a total value of $597,375.00.

Akero Therapeutics Stock Performance

Akero Therapeutics stock opened at $46.10 on Monday. The stock has a 50-day simple moving average of $47.05 and a 200 day simple moving average of $46.66. The company has a quick ratio of 12.66, a current ratio of 12.66 and a debt-to-equity ratio of 0.02. Akero Therapeutics, Inc. has a 12-month low of $21.34 and a 12-month high of $58.40. The stock has a market capitalization of $3.69 billion, a price-to-earnings ratio of -23.05 and a beta of -0.29.

Akero Therapeutics (NASDAQ:AKRO) last released its quarterly earnings results on Friday, August 8th. The company reported ($0.86) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.11. During the same period in the prior year, the firm earned ($0.81) earnings per share. On average, research analysts anticipate that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

AKRO has been the subject of a number of research reports. Wall Street Zen upgraded Akero Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday. Cowen initiated coverage on Akero Therapeutics in a research report on Monday, August 4th. They issued a “buy” rating for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Akero Therapeutics in a research report on Saturday, September 27th. TD Cowen initiated coverage on Akero Therapeutics in a research report on Monday, August 4th. They issued a “buy” rating and a $76.00 price objective for the company. Finally, HC Wainwright initiated coverage on Akero Therapeutics in a research report on Thursday, September 4th. They issued a “buy” rating and a $72.00 price objective for the company. Eight investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Akero Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $81.14.

Institutional Investors Weigh In On Akero Therapeutics

Several institutional investors have recently bought and sold shares of the company. PNC Financial Services Group Inc. lifted its stake in Akero Therapeutics by 17.7% in the 2nd quarter. PNC Financial Services Group Inc. now owns 1,952 shares of the company’s stock valued at $104,000 after acquiring an additional 294 shares in the last quarter. GF Fund Management CO. LTD. lifted its stake in Akero Therapeutics by 21.9% in the 1st quarter. GF Fund Management CO. LTD. now owns 1,787 shares of the company’s stock valued at $72,000 after acquiring an additional 321 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Akero Therapeutics by 14.5% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,664 shares of the company’s stock valued at $114,000 after acquiring an additional 338 shares in the last quarter. Amalgamated Bank lifted its stake in Akero Therapeutics by 19.0% in the 1st quarter. Amalgamated Bank now owns 2,570 shares of the company’s stock valued at $104,000 after acquiring an additional 410 shares in the last quarter. Finally, Summit Investment Advisors Inc. lifted its stake in Akero Therapeutics by 6.3% in the 1st quarter. Summit Investment Advisors Inc. now owns 7,542 shares of the company’s stock valued at $305,000 after acquiring an additional 450 shares in the last quarter.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.